Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
NOVA:FRA
Novo Nordisk A/S
36,04 €
+4,46%
(+1,54) 1D
30-апр., 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOVA...
Open
34,18 €
High
36,50 €
Low
34,18 €
Mkt. cap
149,89 млд
Avg. vol.
3,02 миң
Volume
3,39 миң
52-wk high
71,80 €
52-wk low
30,45 €
No. of employees
69 миң
News stories
From sources across the web
Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees69,2 миң
Founded1923-ж., 21-дек.
HeadquartersBagsværd, Capital Region of Denmark, Дания
SectorPharmaceutical industry
Websitenovonordisk.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
2025-ж. мар.
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
Revenue
78,09 млд
76,86 млд
74,98 млд
79,14 млд
Cost of goods sold
12,89 млд
12,85 млд
14,47 млд
14,17 млд
Cost of revenue
12,89 млд
12,85 млд
14,47 млд
14,17 млд
Research and development expenses
10,31 млд
11,69 млд
11,49 млд
12,67 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16,11 млд
18,85 млд
15,76 млд
17,14 млд
Operating expense
26,41 млд
30,56 млд
27,25 млд
29,73 млд
Total operating expenses
39,30 млд
43,41 млд
41,72 млд
43,90 млд
Operating income
38,79 млд
33,45 млд
33,25 млд
35,24 млд
Other non operating income
-
-
1,53 млд
-241,00 млн
EBT including unusual items
37,03 млд
33,80 млд
25,52 млд
34,18 млд
EBT excluding unusual items
37,03 млд
33,80 млд
35,09 млд
37,62 млд
Income tax expense
8,00 млд
7,30 млд
5,51 млд
7,29 млд
Effective tax rate
21,60%
21,60%
21,60%
21,34%
Other operating expenses
-14,00 млн
23,00 млн
-
-81,00 млн
Net income
29,03 млд
26,50 млд
20,01 млд
26,89 млд
Net profit margin
37,18%
34,48%
26,68%
33,98%
Earnings per share
6,53
5,96
4,50
6,04
Interest and investment income
3,42 млд
5,31 млд
307,00 млн
4,41 млд
Interest expense
-3,86 млд
-4,96 млд
-
-4,97 млд
Net interest expenses
-433,00 млн
356,00 млн
307,00 млн
-560,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
42,62 млд
37,65 млд
36,49 млд
36,66 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer